MK-1084, Merck’s investigational KRAS G12C inhibitor, showed a manageable safety profile along with antitumor activity in the ...

In this video interview, Ron Lanton, partner, Lanton Law, discusses how a potential increase in drug costs could affect the ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights the potential of artificial intelligence in ...

In a post-hoc analysis from the Phase III ARANOTE trial, new results show metastatic castration-sensitive prostate cancer ...

For the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer, patritumab deruxtecan did not meet statistical significance for overall survival in the HERTHENA-Lung02 ...

Pimicotinib, an investigational colony stimulating factor-1 receptor inhibitor being developed by Abbisko Therapeutics and licensed by Merck KGaA, met MANEUVER’s primary endpoint of objective response ...

Developing a clinical trial’s effective monitoring plan can be overwhelming. The FDA acknowledges that while they require monitoring, their “regulations are not specific on how monitoring should be ...

A blend of FSO and FSP models in the landscape of artificial intelligence can ensure CROs stay up to date with the unique ...